Company intelligence / Profile preview

RevMAb Biosciences

South San Francisco, California, United Statesrevmab.com ↗

Ownership: Private
Development stage: Commercial

Overview

RevMAb has commercialized a broad portfolio of highly specific rabbit and goat recombinant monoclonal antibodies validated for applications such as IHC, ELISA, Western blotting. Their proprietary platform enables development of mutation-specific reagents with high sensitivity/specificity. No clinical trial results as they do not develop therapeutics.

Therapeutic areas: Oncology
Modalities: AntibodyMonoclonal antibodyRecombinant protein
Industry: Protein Biomarker Diagnostics

Partnerships

Distribution partnerships with companies like AdipoGen Life Sciences

Beyond the preview

Go deeper on RevMAb Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RevMAb Biosciences.